280 related articles for article (PubMed ID: 9022792)
1. Structure-based design of a new bisintercalating anthracycline antibiotic.
Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
[TBL] [Abstract][Full Text] [Related]
2. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic.
Leng F; Priebe W; Chaires JB
Biochemistry; 1998 Feb; 37(7):1743-53. PubMed ID: 9485299
[TBL] [Abstract][Full Text] [Related]
3. A new bisintercalating anthracycline with picomolar DNA binding affinity.
Portugal J; Cashman DJ; Trent JO; Ferrer-Miralles N; Przewloka T; Fokt I; Priebe W; Chaires JB
J Med Chem; 2005 Dec; 48(26):8209-19. PubMed ID: 16366602
[TBL] [Abstract][Full Text] [Related]
4. Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy.
Robinson H; Priebe W; Chaires JB; Wang AH
Biochemistry; 1997 Jul; 36(29):8663-70. PubMed ID: 9289011
[TBL] [Abstract][Full Text] [Related]
5. Structure of a DNA-bisdaunomycin complex.
Hu GG; Shui X; Leng F; Priebe W; Chaires JB; Williams LD
Biochemistry; 1997 May; 36(20):5940-6. PubMed ID: 9166763
[TBL] [Abstract][Full Text] [Related]
6. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
7. Exploiting anthracycline scaffold for designing DNA-targeting agents.
Priebe W; Fokt I; Przewloka T; Chaires JB; Portugal J; Trent JO
Methods Enzymol; 2001; 340():529-55. PubMed ID: 11494869
[No Abstract] [Full Text] [Related]
8. Parsing the free energy of anthracycline antibiotic binding to DNA.
Chaires JB; Satyanarayana S; Suh D; Fokt I; Przewloka T; Priebe W
Biochemistry; 1996 Feb; 35(7):2047-53. PubMed ID: 8652545
[TBL] [Abstract][Full Text] [Related]
9. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
10. Antitumor agents. 3. Design, synthesis, and biological evaluation of new pyridoisoquinolindione and dihydrothienoquinolindione derivatives with potent cytotoxic activity.
Bolognese A; Correale G; Manfra M; Lavecchia A; Mazzoni O; Novellino E; La Colla P; Sanna G; Loddo R
J Med Chem; 2004 Feb; 47(4):849-58. PubMed ID: 14761187
[TBL] [Abstract][Full Text] [Related]
11. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
Taatjes DJ; Fenick DJ; Koch TH
J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
[TBL] [Abstract][Full Text] [Related]
12. New findings in the study on the intercalation of bisdaunorubicin and its monomeric analogues with naked and nucleus DNA.
Haj HT; Salerno M; Priebe W; Kozlowski H; Garnier-Suillerot A
Chem Biol Interact; 2003 Jun; 145(3):349-58. PubMed ID: 12732461
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance.
Fang L; Zhang G; Li C; Zheng X; Zhu L; Xiao JJ; Szakacs G; Nadas J; Chan KK; Wang PG; Sun D
J Med Chem; 2006 Feb; 49(3):932-41. PubMed ID: 16451059
[TBL] [Abstract][Full Text] [Related]
14. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of daunorubicin analogues containing truncated aromatic cores and unnatural monosaccharide residues.
Fan E; Shi W; Lowary TL
J Org Chem; 2007 Apr; 72(8):2917-28. PubMed ID: 17373847
[TBL] [Abstract][Full Text] [Related]
16. Circumvention of the multidrug-resistance protein (MRP-1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells.
Mansilla S; Rojas M; Bataller M; Priebe W; Portugal J
Biochem Pharmacol; 2007 Apr; 73(7):934-42. PubMed ID: 17217917
[TBL] [Abstract][Full Text] [Related]
17. Oxazolinodoxorubicin - a promising new anthracycline.
Lukawska M; Klopotowska D; Milczarek M; Wietrzyk J; Studzian K; Szmigiero L; Porebska A; Oszczapowicz I
Anticancer Res; 2012 Jul; 32(7):2959-65. PubMed ID: 22753760
[TBL] [Abstract][Full Text] [Related]
18. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effects of daunorubicin and WP631 on transcription.
Portugal J; MartÃn B; Vaquero A; Ferrer N; VillamarÃn S; Priebe W
Curr Med Chem; 2001 Jan; 8(1):1-8. PubMed ID: 11172687
[TBL] [Abstract][Full Text] [Related]
20. Sp1 transcription factor as a target for anthracyclines: effects on gene transcription.
Mansilla S; Portugal J
Biochimie; 2008 Jul; 90(7):976-87. PubMed ID: 18226599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
